

Curriculum Vitae

Personal information **Patricia McGettigan**

Work experience

1. Queen Mary University of London
 - Start date: 082023
 - End date:
 - Position: Professor of Clinical Pharmacology and Medical Education
 - Activities: Research: drug utilisation; medicines adverse effects; medicines regulation
 - Teaching: QMUL Head of MBBS clinical pharmacology and therapeutics teaching; Module lead, Clinical Trials and Regulatory affairs Clinical: Consultant Physician at Barts Health NHS Trust
 - Country: United Kingdom
- 2.
3. Employer: Queen Mary University of London
 - Start date: 082016
 - End date: 072023
 - Position: Associate Professor: Clinical Pharmacology and Medical Education
 - Activities: Research: drug utilisation; medicines adverse effects; medicines regulation
 - Teaching: QMUL Head of MBBS clinical pharmacology and therapeutics teaching; Module lead, Clinical Trials and Regulatory affairs Clinical: Consultant Physician at Barts Health NHS Trust
 - Country: United Kingdom
4. Employer: Queen Mary University of London
 - Start date: 102011
 - End date: 072016
 - Position: Senior Lecturer in Clinical Pharmacology
 - Activities: Research & teaching
 - Country: United Kingdom
5. Employer: Queen Mary University of London
 - Start date: 102011
 - End date:
 - Position: Consultant Physician, Barts Health NHS Trust
 - Activities: In_patient and out_patient clinical care in cardiology and HIV_metabolic medicine, including in 2020, inpatient care for patients with COVID_19
 - Country: United Kingdom
6. Employer: Hull York Medical School, University of Hull and University of York
 - Start date: 072006
 - End date: 092011
 - Position: Senior Lecturer in Medicine and Medical Education
 - Activities: Research & teaching
 - Country: United Kingdom
7. Employer: Hull York Medical School, University of Hull and University of York
 - Start date: 072006
 - End date: 092011
 - Position: Honorary Consultant Physician, North Lincolnshire and Goole Hospitals NHS Foundation Trust
 - Activities: Out-patient clinical care
 - Country: United Kingdom
8. Employer: School of Medicine and Public Health, University of Newcastle; Calvary Mater Hospital, New South Wales, Australia
 - Start date: 022001
 - End date: 062006
 - Position: Senior Lecturer & Staff Specialist
 - Activities: Research & teaching; In_patient and out_patient clinical care
 - Country: Australia
9. Employer: In_patient and out_patient clinical care
 - Start date: 081997
 - End date: 012001
 - Position: Research Academic; Medicines Evaluator; Registrar in Clinical Toxicology; Senior Medical Registrar
 - Activities: Research & teaching; Medicines Evaluation; In_patient and out_patient clinical care
 - Country: Australia
10. Employer: Departments of General Medicine and Pharmacology and Therapeutics, St. James's Hospital and University of Dublin, Trinity College, Dublin, Ireland
 - Start date: 081993
 - End date: 071997
 - Position: Medical Registrar and MD candidate
 - Activities: MD:'Pharmacoepidemiology _ an Irish perspective' research; MBBS student teaching; In_patient and out_patient clinical care
 - Country: Ireland

Education and training

1. Subject: University of Dublin, Trinity College
 - Start date: 081993

- End date: 061997
 - Qualification: Doctor of Medicine
 - Organisation: Pharmacoepidemiology; drug utilisation; adverse events; clinical medicine
 - Country: Ireland
2. Subject: University of Dublin, Trinity College
- Start date: 101984
 - End date: 061990
 - Qualification: MB, BCh, BAO, BA
 - Organisation: Medicine
 - Country: Ireland
3. Subject: University of Dublin, Trinity College
- Start date: 101977
 - End date: 061981
 - Qualification: BSc (Pharmacy)
 - Organisation: Pharmacy
 - Country: Ireland

Additional information

Publications

[Sales and regulatory status of fixed dose combination psychotropic drugs in India: a retrospective longitudinal study](#)

P Bogowicz, A Mehta, S Choudhary, P Brhlikova, P Roderick, P McGettigan, HH Farooqui, AN Sharma, AM Pollock.

Journal of Pharmaceutical Policy and Practice 17 (1), 2372089

[Statistical methods leveraging the hierarchical structure of adverse events for signal detection in clinical trials: a scoping review of the methodological literature](#)

L de Abreu Nunes, R Hooper, P McGettigan, R Phillips

BMC Medical Research Methodology 24 (1), 253

[Temporal trend of first-line drug choice and treatment continuity for hypertension among citizens 75 years or over-a register-based, cohort study](#)

SK Nielsen, M Lamberts, N Nouhravesh, MH Jensen, JE Strange, G Gislason, P McGettigan, A Holt.

International Journal of Cardiology 408, 132137

[Long-term cardiovascular risk associated with treatment of attention-deficit/hyperactivity disorder in adults](#)

A Holt, JE Strange, PV Rasmussen, N Nouhravesh, SK Nielsen, ... P McGettigan, M Schou, M Lamberts

Journal of the American College of Cardiology 83 (19), 1870-1882.

[Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study](#)

A Holt, N Nouhravesh, JE Strange, S Kinnberg Nielsen, AM Schjerning, ... P McGettigan, M Lamberts

European Heart Journal 45 (6), 475-484.

Holt A, Blanche P, Jensen AKG, et al. Adverse events associated with co-prescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: A case_crossover study. Ann Intern Med. (2022). doi: 10.7326/M21_3445. PMID: 35436155. Morales DR, Moreno-Martos D, Matin M, McGettigan P. Health conditions in adults with HIV compared with the general population: A population_based cross_sectional analysis. (2022) Lancet EClinicalMedicine 47, 101392 Holt A, Blanche P, Zareini B, et al. (2022) Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non_vitamin K oral anticoagulants. Heart; 108:626_632. Jonker CJ, de Vries ST, van den Berg HM, et al. (2021). Capturing Data in Rare Disease Registries to Support Regulatory Decision Making: A Survey Study Among Industry and Other Stakeholders. Drug Saf. 44(8):853_861. doi: 10.1007/s40264_021_01081_z Holt A, Blanche P, Jensen AKG, Nouhravesh N, Rajan D, Jensen MH, El_Sheikh M, Schjerning AM, Schou M, Gislason G, Torp_Pedersen C, McGettigan P, Lamberts M. Adverse events associated with co-prescription of phosphodiesterase type 5 inhibitors and oral organic nitrates in male patients with ischemic heart disease: A case_crossover study. Ann Intern Med. (2022). doi: 10.7326/M21_3445. PMID: 35436155. Holt A, Blanche P, McGettigan P, Lamberts M (2021). Temporal changes in myocardial infarction diagnostic criteria do not account for the lack of long_term beta_blocker effect on cardiovascular prognosis. Eur Heart J 10.1093/eurheartj/ehab260 Holt A, Blanche P, Zareini B, Rajan D, El_Sheikh M, Schjerning AM, Schou M, Torp_Pedersen C, McGettigan P, Gislason GH, Lamberts M. (2021). Effect of long_term beta_blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study. Eur Heart J. Vol. 42, (9): 907 _ 914. 10.1093/eurheartj/ehaa1058 Hodges G, Pallisgaard J, Schjerning Olsen AM, McGettigan P, Andersen M, Krogager M, Kragholm K, Køber L et al. (2020) . Association between biomarkers and COVID_19 severity and mortality: A nationwide Danish cohort study. BMJ Open vol. 10 , (12) 10.1136/bmjopen_2020_041295 Robson J, Moss N, McGettigan P, Beardsley SJ, Lovegrove E, Dezateux C (2020). First do no harm: Valproate and medicines safety in pregnancy. British Journal of General Practice vol. 70, (699) 477 _ 478. 10.3399/bjgp20X712673 McGettigan P, Ferner RE (2020). Painful perianal ulcers with nicorandil. The BMJ vol. 370. 10.1136/bmj.m3351 Schjerning AM, McGettigan P, Gislason G (2020). Cardiovascular effects and safety of (non_aspirin) NSAIDs. Nature Reviews Cardiology vol. 17 (9) 574 _ 584. 10.1038/s41569_020_0366_z Lovegrove E, Robson J, McGettigan P (2020) . Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: A cross_sectional study in primary care. British Journal of General Practice vol. 70 (700) 10.3399/bjgp20X712997 Ferner R, McGettigan P (2020). The patient who reports a drug allergy. The BMJ vol. 368. 10.1136/bmj.l6791 Schjerning Olsen AM, McGettigan P, Gislason G. (2020) Cardiovascular effects and safety of (non_aspirin) NSAIDs. Nature Reviews Cardiology; https://doi.org/10.1038/s41569_020_0366_z Ferner RE, McGettigan P. (2020) Drug allergies. BMJ; 368 doi: <https://doi.org/10.1136/bmj.l6791> Schjerning Olsen AM, McGettigan P, Gerds TA, Fosbøl EL, Olesen JB, Sindet_Pedersen C, Staerk L, Hansen ML Pallisgaard JL Køber L, Torp_Pedersen C, Gislason GH, Lamberts M . (2019)

Risk of gastrointestinal bleeding associated with oral anticoagulation and non-steroidal anti-inflammatory drugs in patients with atrial fibrillation: a nationwide study. *European Heart Journal _ Cardiovascular Pharmacotherapy* <https://doi.org/10.1093/ehjcvp/pvz069> Schuster Bruce C, Brhlikova P, Heath J, McGettigan P. (2019) The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018. *PLoS Med.* 2019; 16(9):e1002873. doi:10.1371/journal.pmed.1002873 McGettigan P, Alonso CO, Plueschke K, Castillon M, Nogueras DZ, Bahri P, Kurz X, Mol P. (2019) Patient registries: an underused resource for medicines evaluation: operational proposals for increasing the use of patient registries in regulatory assessments. *Drug Safety* 2019; 42:1343-51. https://doi.org/10.1007/s40264_019_00848_9. Barcella CA, Lamberts M, McGettigan P, et al. (2019) Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy—A nationwide study in patients with osteoarthritis. *Basic Clin Pharmacol Toxicol.* 2019; 124: 629–641. <https://doi.org/10.1111/bcpt.13182> Alonso Olmo C, McGettigan P, Kurz X. (2019) Barriers and opportunities for use of patient registries in medicines regulation. *Clin Pharmacol Ther.* 2019; 106(1): 39–42 Morales D, Pacurariu A, Slattery J, Pinheiro L, McGettigan P, Kurz X. (2019) Association between peripheral neuropathy and exposure to oral fluoroquinolone or co-amoxiclav therapy: population-based nested case-control study. *JAMA Neurol.* 2019;76(7):827-833. doi:10.1001/jamaneurol.2019.0887 Ferner RE, McGettigan P. (2018) Adverse Drug Reactions. *BMJ*; 363:k4051. doi: 10.1136/bmj.k4051. PMID: 30401691. Pacurariu A, Plueschke K, McGettigan P, et al. (2018) Electronic healthcare databases in Europe: descriptive analysis of characteristics and potential for use in medicines regulation. *BMJ Open* <https://bmjopen.bmj.com/content/8/9/e023090> Plueschke K, McGettigan P, Pacurariu A, Kurz X, Cave A. (2018) EU-funded initiatives for Real World Evidence: Descriptive analysis of their characteristics and relevance for regulatory decision-making. *BMJ Open* <https://bmjopen.bmj.com/content/8/6/e021864>.info McGettigan P, Roderick P, Kadam A et al. (2018). Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India. *Br J Clin Pharmacol* 10.1111/bcp.13503 McGettigan P, Roderick P, Kadam A et al. (2017). Access, Watch, and Reserve antibiotics in India: challenges for WHO stewardship. *The Lancet Global Health* vol. 5, (11) e1075_e1076. 10.1016/S2214-109X(17)30365_0

Projects

Memberships

Medical Board of New South Wales, Australia: Specialist registration in General Medicine & Clinical Pharmacology
 Medical Council of Ireland: Fully registered medical practitioner; Specialist registration in Clinical Pharmacology
 General Medical Council, England: Fully registered medical practitioner with a license to practice; Specialist registration in Clinical Pharmacology
 Fellowship; Royal Australasian College of Physicians
 Fellowship; Royal College of Physicians of Ireland
 Senior Fellowship; The Higher Education Academy, United Kingdom.
 Fellowship: British Pharmacological Society

Other Relevant Information

Visiting Professor, University of Copenhagen, Herlev & Gentofte Hospital, Denmark